Publicaciones en colaboración con investigadoras/es de Centro Medico Teknon (17)

2024

  1. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management

    United European Gastroenterology Journal, Vol. 12, Núm. 1, pp. 122-138

2023

  1. A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer

    Molecular Cancer

  2. Etiopathogenesis of chronic kidney disease-associated pruritus: putting the pieces of the puzzle together

    Nefrologia, Vol. 43, Núm. 1, pp. 48-62

2021

  1. Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg)

    The American journal of gastroenterology, Vol. 116, Núm. 6, pp. 1220-1229

  2. European registry on helicobacter pylori management: Effectiveness of first and second-line treatment in Spain

    Antibiotics, Vol. 10, Núm. 1, pp. 1-15

2020

  1. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg)

    Helicobacter, Vol. 25, Núm. 5

  2. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg)

    Helicobacter, Vol. 25, Núm. 3

2019

  1. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: A prospective cohort study

    European Heart Journal, Vol. 40, Núm. 39, pp. 3222-3232B

  2. Document on a comprehensive approach to type 2 diabetes mellitus

    Endocrinologia, Diabetes y Nutricion, Vol. 66, Núm. 7, pp. 443-458

2017

  1. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia

    Clinical Microbiology and Infection, Vol. 23, Núm. 1, pp. 49.e1-49.e8

  2. Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance

    Clinical Microbiology and Infection, Vol. 23, Núm. 9, pp. 672.e1-672.e11

2016

  1. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre prospective cohort

    Clinical Microbiology and Infection, Vol. 22, Núm. 8, pp. 733.e1-733.e8

  2. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study

    Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 63, Núm. 8, pp. 397-408

2015

  1. Candida tropicalis bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance

    Journal of Infection, Vol. 71, Núm. 3, pp. 385-394

2014

  1. Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study

    Clinical Endocrinology, Vol. 81, Núm. 6, pp. 883-890

2009

  1. Association between Mycobacterium avium subsp. paratuberculosis DNA in blood and cellular and humoral immune response in inflammatory bowel disease patients and controls

    International Journal of Infectious Diseases, Vol. 13, Núm. 2, pp. 247-254

2008

  1. On the prevalence of M. avium subspecies paratuberculosis DNA in the blood of healthy individuals and patients with inflammatory bowel disease

    PLoS ONE, Vol. 3, Núm. 7